Omnicare (NYSE: OCR)‘s stock had its “outperform” rating reaffirmed by Cowen in a research note issued on Tuesday.

Separately, analysts at JPMorgan Chase raised their price target on shares of Omnicare to $45.00 in a research note to investors on Wednesday, February 20th. They now have an “overweight” rating on the stock.

Six research analysts have rated the stock with a buy rating, and four have assigned a hold rating to the company. The stock presently has a consensus rating of “overweight” and a consensus target price of $42.71.

Omnicare opened at 37.92 on Tuesday. Omnicare has a 1-year low of $29.24 and a 1-year high of $40.00. The stock’s 50-day moving average is currently $38.5. The company has a market cap of $3.968 billion and a price-to-earnings ratio of 21.96.

Omnicare last released its earnings data on Tuesday, February 19th. The company reported $0.86 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.85 by $0.01. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter last year, the company posted $0.58 earnings per share. Omnicare’s revenue was down 1.7% compared to the same quarter last year. Omnicare has set its FY13 guidance at $3.47-3.57 EPS. On average, analysts predict that Omnicare will post $3.54 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Friday, March 22nd. Investors of record on Thursday, March 7th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 1.48%. The ex-dividend date is Tuesday, March 5th.

Omnicare, Inc. (Omnicare) is a pharmaceutical services company. The Company is a provider of pharmaceuticals and related pharmacy and ancillary services to long-term healthcare institutions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.